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therapeutic nihilism — after all, 
if there is no treatment, what can 
be done? And without an Ebola-
specific antiviral medication, of 
what use are infectious-disease 
clinicians? Without oxygen, let 
alone mechanical ventilators, 
how can acute and critical care 
clinicians possibly contribute?
We have traveled several times 
to West Africa and done primary 
patient care in treatment centers 
and hospitals in Guinea (Conakry 
and Guéckédou), Sierra Leone 
(Kenema, Bo, and Daru), and Li-
beria (Monrovia, Bong, and Foya). 
Before each trip, as we prepared 
to go to the front lines of Ebola 
medical care as part of World 
Health Organization and Médecins 
sans Frontières clinical teams, 
we, too, felt a certain unease about 
treating a highly transmissible 
infection for which there is no 
vaccine, no specific therapy, and 
a high mortality rate. Yet we also 
appreciated that most viral ill-
nesses, and certainly most criti-
cal illnesses, have no specific 
therapy. And after spending much 
of the past 5 months treating pa-
tients with Ebola virus disease 
(EVD), we are convinced that it’s 
possible to save many more pa-
tients. Our optimism is fueled by 
the observation that supportive 
care is also specific care for EVD 
— and in all likelihood reduces 
mortality. Unfortunately, many 
patients in West Africa continue 
to die for lack of the opportunity 
to receive such basic care.
EVD presents much as many 
other viral infections do, with 
nonspecific signs such as fever, 
asthenia, and body aches. After a 
few days, however, the predomi-
nant clinical syndrome is a se-
vere gastrointestinal illness with 
vomiting and diarrhea. Volume 
depletion with a range of meta-
bolic disorders ensues, and hypo-
volemic shock ultimately occurs.
A common assumption is that 
a lack of material resources con-
stitutes the dominant barrier to 
clinical care. That is not the case. 
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The Ebola outbreak that is ravaging West Africa is a daily staple of the lay press and of scholarly 
medical publications. Ebola evokes fear among both 
the public and clinicians. It also evokes a sort of 
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Intravenous catheters, fluids, and 
electrolyte replacement are readily 
available but thus far are being 
used much too sparingly. When 
patients can no longer drink, 
placement of an intravenous 
catheter and delivery of appropri-
ate replacement solutions are re-
quired, but we have seen many 
critically ill patients die without 
adequate intravenous fluid resus-
citation. On the occasions when 
we’ve been able to obtain basic 
biochemistry measurements, we 
have commonly found extreme 
serum sodium and potassium ab-
normalities. With the current fo-
cus on diagnosis of Ebola, we are 
routinely measuring Ebola viral 
loads in some of the world’s most 
logistically challenged medical 
care environments using advanced 
polymerase-chain-reaction assays 
that are unavailable in most 
 tertiary care centers. Yet we are 
not routinely deploying basic bio-
chemical and hematologic diag-
nostic capabilities. We could do 
so. Simple interventions can 
prevent deaths attributable to 
hypovolemia and metabolic ab-
normalities. The high mortality 
from Ebola continues to reflect 
the natural history of the ill-
ness, not an inability to alter its 
course.
We believe we can and must 
do better in providing supportive 
care. There is a historical bias 
against aggressive interventions, 
including intravenous cannulation, 
for many transmissible illnesses. 
Percutaneous injury to health care 
workers does carry substantial 
risk, but such risks are not spe-
cific to Ebola. It is now ethically 
untenable and medically unjustifi-
able to deny life-supporting 
therapies to patients with human 
immunodeficiency virus (HIV) 
infection, but only a few decades 
ago, the fear of HIV and the per-
ception that AIDS was uniformly 
fatal led to an approach similar to 
that currently being taken for EVD.
Another common assumption 
is that a lack of skilled personnel 
constitutes a barrier to clinical 
care; this assumption is in fact 
valid. There is an insufficient 
number of clinicians to meet the 
primary and routine care needs 
of the population. Yet the skills 
needed to care for patients with 
Ebola are fundamental acute care 
skills, not the privileged domain 
of tropical medicine, infectious 
disease, or critical care.
There has recently been im-
mense media, public, and medi-
cal attention to specific treat-
ments for Ebola virus infection. 
Although these experimental in-
terventions represent important 
potential treatments, they also 
reflect our seemingly innate fo-
cus on developing magic bullets. 
It seems that focusing on reduc-
ing mortality in the existing 
“control group” by applying the 
current standard of care is less 
interesting, even if much more 
likely to be effective. Though we 
recognize the potential incremen-
tal value of new antiviral options, 
we believe that EVD requires a 
greater focus on available basic 
care. We recommend that experi-
mental therapy be introduced on 
a foundation of very good sup-
portive care; indeed, in assessing 
these therapies’ effectiveness, it 
will be critical to consider the ex-
tent to which historical controls 
received such supportive care.
With nearly 5000 cases to 
date, more than half of them in 
the past month, there is a press-
ing need to gain control of this 
epidemic. As we mourn the loss 
of nearly 3000 victims thus far, 
there is an urgency to prevent 
new cases, but also to reduce the 
case fatality rate.
Public health interventions 
including characterizing the out-
break epidemiology, contact trac-
ing, social mobilization, and pub-
lic education are essential steps 
in stopping Ebola and will ulti-
mately save many more lives 
than can be saved by individual 
patient care. The high mortality 
associated with Ebola, however, 
threatens the ability to perform 
many of these tasks. The public 
is reluctant to engage in contact 
tracing, infected persons are hes-
itant to present for treatment, 
and clinicians are frightened to 
provide care. Although infection 
prevention and outbreak control 
are essential components of the 
Ebola response, they need not be 
at odds with equally essential 
syndrome-specific therapy for peo-
ple who are already infected. Ex-
cellent clinical care and improved 
outcomes will result in improved 
community compliance, will help 
to break transmission chains, 
and will lead to a greater will-
ingness of health care workers to 
engage in care delivery. To quote 
William Osler, “The best prepa-
ration for tomorrow is to do to-
day’s work superbly well.”
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